Intellipharmaceutics International Inc. (IPCIQ)
OTC PINK OTC PINK Primary Summary
Intellipharmaceutics International Inc. (IPCIQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Intellipharmaceutics International Inc. ever had a stock split?
Intellipharmaceutics International Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Isa Odidi MBA, Ph.D. CEO | OTC PINK Exchange | - ISIN |
| Canada Country | 11 Employees | - Last Dividend | 14 Sep 2018 Last Split | - IPO Date |
Overview
Intellipharmaceutics International Inc., established in 1998 and headquartered in Toronto, Canada, is a pharmaceutical company engaged in the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage drugs. Operating mainly in the United States, the company leverages its patented Hypermatrix technology to create a variety of drug delivery systems and product candidates. It aims to address therapeutic areas such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain, showcasing a commitment to improving healthcare solutions through advanced pharmacological research.
Products and Services
- Focalin XR: A dexmethylphenidate hydrochloride extended-release capsule designed for treating hyperactivity disorder.
- Keppra XR: An extended-release tablet of levetiracetam that helps in treating partial-onset seizures in patients with epilepsy.
- Effexor XR: A venlafaxine hydrochloride extended-release capsule for the treatment of depression.
- Protonix: This pantoprazole sodium delayed-release tablet is used for the treatment of gastroesophageal reflux disease (GERD).
- Glucophage XR: A metformin hydrochloride extended-release tablet for managing type 2 diabetes.
- Seroquel XR: An extended-release tablet of quetiapine fumarate for treating schizophrenia, bipolar disorder, and major depressive disorders.
- Lamictal XR: Lamotrigine extended-release tablets aimed at treating epilepsy.
- Pristiq: A desvenlafaxine extended-release tablet developed for the treatment of depression.
- Coreg CR: A carvedilol phosphate extended-release capsule for the treatment of heart failure and hypertension.
- Ranexa: Ranolazine extended-release tablets designed for the treatment of chronic angina.
- OxyContin: Oxycodone hydrochloride controlled-release capsules for pain management. The listing of OxyContin appears twice, indicating a focus on pain treatment options.
- Regabatin XR: A pregabalin extended-release capsule for managing neuropathic pain.
In addition to these marketed products, Intellipharmaceutics is continuously engaged in development efforts, aiming to expand its portfolio and address unmet medical needs. Through its license and commercialization agreement with Par Pharmaceutical Inc., Intellipharmaceutics ensures its products reach a broader market, thus contributing to the healthcare industry with innovative, effective pharmaceutical solutions.
